COVID-19 has transformed the healthcare experience for patients in India. Nearly 3000 Indians were interviewed and we found that the pandemic caused unprecedented growth in digital healthcare. This was a trend that had been slowing down before COVID-19. This past year, 28 percent of respondents reported that their access to healthcare has improved since the COVID-19 pandemic.
Biopharma is facing a new economic environment that requires change. The industry is at an inflection point, where it must achieve the impossible due to rising costs for New Science and patient care.
Deliver more affordable, customized, and effective treatments, while also adapting to changes in crisis management.
Technology giants continue to look for industry leaders to replace them. Biopharma companies require new solutions to navigate this complex landscape.